Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Video

Nephrectomy is often the initial treatment for renal-cell cancer (RCC), but systemic therapy is frequently required for advanced RCC. Single-agent targeted therapies are only somewhat effective, which led to the development of immunotherapies and combination therapies (which include immunotherapies). Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss the clinical advantages of combination therapies in patients with advanced RCC.
Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their roles and responsibilities within their academic oncology centers as valuable members of a multidisciplinary team that helps patients successfully navigate the spectrum of patient care. They also detail how they apply the principles of patient-centered care to improve outcomes for patients.
The use of targeted agents and immunotherapy has transformed the treatment of NSCLC
Encouraging shared decision making by NSCLC by educating and counseling patients and their families
Reflex NGS testing is now the standard of care for many patients with NSCLC
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their support for the use of PARP inhibitors as maintenance therapy in ovarian cancer, and that the optimization of this therapy requires further research to discover the best therapeutic combinations that will be personalized based on patient characteristics.
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, consider the current and future use of immunotherapy, either alone or in combination with other agents such as PARP inhibitors, as first-line maintenance therapy in ovarian cancer.
Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, describe the impact that first-line maintenance therapy has on quality of life in patients with ovarian cancer despite adverse events associated with the treatment, and that frequent communication with the healthcare team during maintenance therapy is critical.
Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their insights on the occurrence and management of the most common hematologic and nonhematologic adverse events associated with several PARP inhibitors that are used as maintenance therapy in ovarian cancer.
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, discuss the benefits and risks of using combination therapy with a PARP inhibitor and bevacizumab as first-line maintenance therapy in ovarian cancer.
Page 1 of 10
Results 1 - 10 of 97